Camlin Fine Sciences Limited has informed the Exchange about Transcript
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Camlin Fine Sciences reported Q1 FY26 revenue of INR423 crores, down from INR437 crores last year, with EBITDA of INR19 crores at a 4.5% margin. Results were hit by a one-time annual maintenance shutdown at Dahej and Tarapur plants, causing ~INR12.5 crores in unabsorbed fixed costs, plus a INR7.5 crore one-time performance bonus to Blends business employees, and ~INR7-8 crores in restart-related margin loss. Management called this a 'one-time' quarter and does not expect another shutdown for 12 months. The vanillin business is stable with 60% current capacity utilization; management expects 70-80% utilization in FY27 and full utilization in FY28, targeting 2,500-3,000 tons at $13-14/kg average realization. Blends business continues to grow, targeting 20% growth with sustainable gross margins of 40-45%. China operations expected to break even by end of FY26, with Europe site costs reducing to ~INR2 crores/quarter next year.
The quarterly results are unlikely to pressure the stock much as the management clearly framed the weak quarter as one-time, with EBITDA recovery expected from Q3 FY26 onwards as vanillin channel stocks clear and Blends growth continues. The 50% U.S. tariff on Indian vanillin remains a key overhang, but management believes they retain a competitive edge given 280% anti-dumping duty on Chinese rivals. Investors should watch for the September-October contract negotiations and capacity utilization trajectory in vanillin.